High-Dose Cisplatin Treatment for Ovarian Cancer
Author Information
Author(s): S. Kehoe, C. Redman, R. Varma, J. Buxton, D. Luesley, G. Blackledge, A. Stanley
Primary Institution: CRC Clinical Trials Unit, Queen Elizabeth Medical Centre, Birmingham, UK
Hypothesis
Is high-dose cisplatin effective in treating ovarian carcinoma without severe neurotoxicity?
Conclusion
High-dose cisplatin can achieve good response rates in ovarian cancer patients with manageable side effects.
Supporting Evidence
- 40% of patients responded to treatment, with 25% achieving a complete response.
- The median duration of response was 44 weeks.
- Neurotoxicity affected seven patients, but most side effects were manageable.
Takeaway
Doctors gave a strong medicine called cisplatin to help people with a type of cancer in their ovaries, and many got better without feeling too sick.
Methodology
Twenty patients with ovarian cancer received three cycles of high-dose cisplatin, with treatment stopped if severe side effects occurred.
Limitations
The study had a small sample size and did not include patients with prior neurotoxicity.
Participant Demographics
Patients aged 26-76 years, median age 51, with various histological types of ovarian cancer.
Statistical Information
P-Value
p<0.002
Confidence Interval
95% confidence limits 19-61%
Statistical Significance
p<0.002
Want to read the original?
Access the complete publication on the publisher's website